{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T08:23:02Z","timestamp":1789806182476,"version":"4.0.1"},"reference-count":148,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T00:00:00Z","timestamp":1628208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R21CA242933"],"award-info":[{"award-number":["R21CA242933"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Since all tumors are unique, they may respond differently to the same treatments. Therefore, it is necessary to study their characteristics individually to find their best treatment options. We built a mathematical model for the interactions between the most common chemotherapy drugs and the osteosarcoma microenvironments of three clusters of tumors with unique immune profiles. We then investigated the effects of chemotherapy with different treatment regimens and various treatment start times on the behaviors of immune and cancer cells in each cluster. Saliently, we suggest the optimal drug dosages for the tumors in each cluster. The results show that abundances of dendritic cells and HMGB1 increase when drugs are given and decrease when drugs are absent. Populations of helper T cells, cytotoxic cells, and IFN-\u03b3 grow, and populations of cancer cells and other immune cells shrink during treatment. According to the model, the MAP regimen does a good job at killing cancer, and is more effective than doxorubicin and cisplatin combined or methotrexate alone. The results also indicate that it is important to consider the tumor\u2019s unique growth rate when deciding the treatment details, as fast growing tumors need early treatment start times and high dosages.<\/jats:p>","DOI":"10.3390\/cells10082009","type":"journal-article","created":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T08:01:42Z","timestamp":1628236902000},"page":"2009","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Investigating Optimal Chemotherapy Options for Osteosarcoma Patients through a Mathematical Model"],"prefix":"10.3390","volume":"10","author":[{"given":"Trang","family":"Le","sequence":"first","affiliation":[{"name":"Department of Mathematics and Statistics, University of Massachusetts Amherst, Amherst, MA 01003, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5221-413X","authenticated-orcid":false,"given":"Sumeyye","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Mathematics and Statistics, University of Massachusetts Amherst, Amherst, MA 01003, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6234-8449","authenticated-orcid":false,"given":"Leili","family":"Shahriyari","sequence":"additional","affiliation":[{"name":"Department of Mathematics and Statistics, University of Massachusetts Amherst, Amherst, MA 01003, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,6]]},"reference":[{"key":"ref_1","unstructured":"American Cancer Society (2021, May 20). Key Statistics for Osteosarcoma. Available online: https:\/\/www.cancer.org\/cancer\/osteosarcoma\/about\/key-statistics.html."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4419-0284-9_1","article-title":"The Epidemiology of Osteosarcoma","volume":"152","author":"Ottaviani","year":"2009","journal-title":"Cancer Treat Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jbo.2017.11.005","article-title":"Advances in limb salvage treatment of osteosarcoma","volume":"10","author":"Yang","year":"2018","journal-title":"J. Bone Oncol."},{"key":"ref_4","unstructured":"PDQ Pediatric Treatment Editorial Board (2002). Osteosarcoma and Malignant Fibrous Histiocytoma of Bone Treatment (PDQ\u00ae): Patient Version, National Cancer Institute."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e345","DOI":"10.3928\/01477447-20200721-05","article-title":"Current Treatment Considerations for Osteosarcoma Metastatic at Presentation","volume":"43","author":"Tsukamoto","year":"2020","journal-title":"Orthopedics"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Marchandet, L., Lallier, M., Charrier, C., Baud\u2019huin, M., Ory, B., and Lamoureux, F. (2021). Mechanisms of Resistance to Conventional Therapies for Osteosarcoma. Cancers, 13.","DOI":"10.3390\/cancers13040683"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13018-016-0500-0","article-title":"A meta-analysis of randomized control trials of surgical methods with osteosarcoma outcomes","volume":"12","author":"He","year":"2017","journal-title":"J. Orthop. Surg. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1200\/JCO.2008.14.0095","article-title":"Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival\u2014A Report From the Children\u2019s Oncology Group","volume":"26","author":"Meyers","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(20)30023-1","article-title":"Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): A multicentre, open-label, single-arm, phase 1\u20132 trial","volume":"21","author":"Davis","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/978-1-4419-0284-9_7","article-title":"The Role of Radiotherapy in Oseosarcoma","volume":"152","author":"Schwarz","year":"2009","journal-title":"Cancer Treat Res."},{"key":"ref_11","first-page":"2","article-title":"Sternal Mass with Respiratory Compromise in a 10-year-old Child","volume":"2","author":"Sharma","year":"2019","journal-title":"J. Bone Soft Tissue Tumors"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Prudowsky, Z.D., and Yustein, J.T. (2020). Recent Insights into Therapy Resistance in Osteosarcoma. Cancers, 13.","DOI":"10.3390\/cancers13010083"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3389\/fimmu.2020.00784","article-title":"The tumor microenvironment in the response to immune checkpoint blockade therapies","volume":"11","author":"Petitprez","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"575264","DOI":"10.3389\/fonc.2020.575264","article-title":"Relevance of Immune Infiltration and clinical outcomes in pancreatic ductal adenocarcinoma subtypes","volume":"10","author":"Liu","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"111836","DOI":"10.18632\/oncotarget.22912","article-title":"Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8\/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1","volume":"8","author":"Palmerini","year":"2017","journal-title":"Oncotarget"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.canlet.2016.01.043","article-title":"Tumor microenvironment and therapeutic response","volume":"387","author":"Wu","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e28518","DOI":"10.4161\/onci.28518","article-title":"Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death","volume":"3","author":"Golden","year":"2014","journal-title":"Oncoimmunology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.bbrc.2009.12.008","article-title":"Application of hyperthermia in addition to ionizing irradiation fosters necrotic cell death and HMGB1 release of colorectal tumor cells","volume":"391","author":"Schildkopf","year":"2010","journal-title":"Biochem. Biophys. Res.Commun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1600-065X.2007.00573.x","article-title":"The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy","volume":"220","author":"Apetoh","year":"2007","journal-title":"Immunol. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/leu.2010.225","article-title":"HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells","volume":"25","author":"Liu","year":"2011","journal-title":"Leukemia"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5723","DOI":"10.1158\/0008-5472.CAN-13-2347","article-title":"HMGB1 enhances immune suppression by facilitating the differentiation and suppressive activity of myeloid-derived suppressor cells","volume":"74","author":"Parker","year":"2014","journal-title":"Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.it.2005.04.009","article-title":"HMGB1: Guiding immunity from within","volume":"26","author":"Dumitriu","year":"2005","journal-title":"Trends Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2147\/ITT.S58064","article-title":"Emerging roles for HMGB1 protein in immunity, inflammation, and cancer","volume":"4","author":"Ranzato","year":"2015","journal-title":"ImmunoTargets Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"476","DOI":"10.2119\/2008-00034.Klune","article-title":"HMGB1: Endogenous danger signaling","volume":"14","author":"Klune","year":"2008","journal-title":"Mol. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"7035045","DOI":"10.1155\/2019\/7035045","article-title":"Current and Emerging Targets in Immunotherapy for Osteosarcoma","volume":"2019","author":"Miwa","year":"2019","journal-title":"J. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic Cell Death in Cancer Therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Ann. Rev. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.3389\/fimmu.2019.01114","article-title":"Innate immune cells: A potential and promising cell population for treating osteosarcoma","volume":"10","author":"Wang","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/pbc.22136","article-title":"The role of interferons in the treatment of osteosarcoma","volume":"54","author":"Whelan","year":"2010","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1080\/08820139.2016.1197242","article-title":"Regulatory T Cells and Cancer: A Two-Sided Story","volume":"45","author":"Wang","year":"2016","journal-title":"Immunol. Investig."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/nrc3838","article-title":"Translational biology of osteosarcoma","volume":"14","author":"Kansara","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1111\/j.1349-7006.2006.00317.x","article-title":"Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5","volume":"97","author":"Tsukahara","year":"2006","journal-title":"Cancer Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.3389\/fonc.2020.01198","article-title":"Immune Landscape of the Tumor Microenvironment Identifies Prognostic Gene Signature CD4\/CD68\/CSF1R in Osteosarcoma","volume":"10","author":"Song","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.3934\/mbe.2021098","article-title":"Immune classification of osteosarcoma","volume":"18","author":"Le","year":"2021","journal-title":"Math. Biosci. Eng."},{"key":"ref_34","first-page":"22906","article-title":"Construction of immune-related gene pairs signature to predict the overall survival of osteosarcoma patients","volume":"12","author":"Khader","year":"2020","journal-title":"Aging"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5384","DOI":"10.1158\/1078-0432.CCR-14-1298","article-title":"Cisplatin-induced antitumor immunomodulation: A review of preclinical and clinical evidence","volume":"20","author":"Adusumilli","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"6017","DOI":"10.1158\/0008-5472.CAN-16-0881","article-title":"Tumor eradication by cisplatin is sustained by CD80\/86-mediated costimulation of CD8+ T cells","volume":"76","author":"Nejad","year":"2016","journal-title":"Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1158\/2326-6066.CIR-17-0235","article-title":"Cisplatin alters antitumor immunity and synergizes with PD-1\/PD-L1 inhibition in head and neck squamous cell carcinoma","volume":"5","author":"Tran","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/S0022-5223(03)00707-4","article-title":"Cisplatin augments cytotoxic T-lymphocyte\u2013mediated antitumor immunity in poorly immunogenic murine lung cancer","volume":"126","author":"Merritt","year":"2003","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"iv79","DOI":"10.1093\/annonc\/mdy310","article-title":"Bone sarcomas: ESMO\u2013PaedCan\u2013EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Casali","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_40","unstructured":"American Cancer Society (2021, June 25). Chemotherapy and Other Drugs for Osteosarcoma. Available online: https:\/\/www.cancer.org\/cancer\/osteosarcoma\/treating\/chemotherapy.html."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Shahriyari, L., and Komarova, N.L. (2013). Symmetric vs. asymmetric stem cell divisions: An adaptation against cancer?. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0076195"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"055001","DOI":"10.1088\/1478-3975\/12\/5\/055001","article-title":"The role of the bi-compartmental stem cell niche in delaying cancer","volume":"12","author":"Shahriyari","year":"2015","journal-title":"Phys. Biol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"016004","DOI":"10.1088\/1478-3975\/aa5a61","article-title":"Modeling dynamics of mutants in heterogeneous stem cell niche","volume":"14","author":"Shahriyari","year":"2017","journal-title":"Phys. Biol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Bollas, A., and Shahriyari, L. (2017). The role of backward cell migration in two-hit mutants\u2019 production in the stem cell niche. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0184651"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1007\/s11538-019-00640-x","article-title":"Mathematical models of cancer: When to predict novel therapies, and when not to","volume":"81","author":"Brady","year":"2019","journal-title":"Bull. Math. Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e1461","DOI":"10.1002\/wsbm.1461","article-title":"Hybrid modeling frameworks of tumor development and treatment","volume":"12","author":"Chamseddine","year":"2020","journal-title":"Wiley Interdiscip. Rev. Syst. Biol. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1142\/S0219525902000572","article-title":"Cellular automaton models of tumor development: A critical review","volume":"5","author":"Moreira","year":"2002","journal-title":"Adv. Complex Syst."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1088\/0951-7715\/23\/1\/R01","article-title":"Nonlinear modelling of cancer: Bridging the gap between cells and tumours","volume":"23","author":"Lowengrub","year":"2009","journal-title":"Nonlinearity"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"20160977","DOI":"10.1098\/rsif.2016.0977","article-title":"Cell dynamics in tumour environment after treatments","volume":"14","author":"Shahriyari","year":"2017","journal-title":"J. R. Soc. Interface"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00285-020-01521-x","article-title":"Implications of immune-mediated metastatic growth on metastatic dormancy, blow-up, early detection, and treatment","volume":"81","author":"Rhodes","year":"2020","journal-title":"J. Math. Biol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/imammb\/dqz009","article-title":"A stochastic model for cancer metastasis: Branching stochastic process with settlement","volume":"37","author":"Frei","year":"2020","journal-title":"Math. Med. Biol. J. IMA"},{"key":"ref_52","first-page":"915","article-title":"Mathematical modeling of regulatory T cell effects on renal cell carcinoma treatment","volume":"18","author":"Caldwell","year":"2013","journal-title":"Discret. Contin. Dyn. Syst.-B"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.jtbi.2015.06.009","article-title":"A model for effects of adaptive immunity on tumor response to chemotherapy and chemoimmunotherapy","volume":"380","author":"Goriely","year":"2015","journal-title":"J. Theor. Biol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jtbi.2011.10.027","article-title":"A mathematical model of tumor\u2013immune interactions","volume":"294","author":"Goriely","year":"2012","journal-title":"J. Theor. Biol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"103619","DOI":"10.1016\/j.compbiomed.2020.103619","article-title":"Mathematical modelling of the role of Endo180 network in the development of metastatic bone disease in prostate cancer","volume":"117","author":"Ji","year":"2020","journal-title":"Comput. Biol. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"9478","DOI":"10.1007\/s10853-019-03537-1","article-title":"Polylactic acid\/sodium alginate\/hydroxyapatite composite scaffolds with trabecular tissue morphology designed by a bone remodeling model using 3D printing","volume":"54","author":"Morales","year":"2019","journal-title":"J. Mater. Sci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2041731419830264","DOI":"10.1177\/2041731419830264","article-title":"A parameterised mathematical model to elucidate osteoblast cell growth in a phosphate-glass microcarrier culture","volume":"10","author":"Burova","year":"2019","journal-title":"J. Tissue Eng."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Le, T., Su, S., Kirshtein, A., and Shahriyari, L. (2021). Data-Driven Mathematical Model of Osteosarcoma. Cancers, 13.","DOI":"10.3390\/cancers13102367"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1756-9966-33-27","article-title":"Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-\u03b3","volume":"33","author":"Pahl","year":"2014","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1089\/jayao.2016.0078","article-title":"Monocytes, Macrophages, and Osteoclasts in Osteosarcoma","volume":"6","author":"Kelleher","year":"2017","journal-title":"J. Adolesc. Young Adult Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Cersosimo, F., Lonardi, S., Bernardini, G., Telfer, B., Mandelli, G.E., Santucci, A., Vermi, W., and Giurisato, E. (2020). Tumor-associated macrophages in osteosarcoma: From mechanisms to therapy. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21155207"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/bjc.2017.356","article-title":"TAMeless traitors: Macrophages in cancer progression and metastasis","volume":"117","author":"Aras","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_63","first-page":"38","article-title":"Immune Environment and Osteosarcoma","volume":"i","author":"Heymann","year":"2012","journal-title":"Colloids Surf. A Physicochem. Eng. Asp."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1158\/0008-5472.CAN-05-4005","article-title":"Distinct role of macrophages in different tumor microenvironments","volume":"66","author":"Lewis","year":"2006","journal-title":"Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/nri3156","article-title":"The role of interleukin-2 during homeostasis and activation of the immune system","volume":"12","author":"Boyman","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"622","DOI":"10.3389\/fimmu.2014.00622","article-title":"Plasticity of \u03b3\u03b4 T cells: Impact on the anti-tumor response","volume":"5","author":"Lafont","year":"2014","journal-title":"Front. Immunol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"103711","DOI":"10.1016\/j.cellimm.2017.10.011","article-title":"The contribution of immune infiltrates and the local microenvironment in the pathogenesis of osteosarcoma","volume":"343","author":"Heymann","year":"2019","journal-title":"Cell. Immunol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Corre, I., Verrecchia, F., Crenn, V., Redini, F., and Trichet, V. (2020). The Osteosarcoma Microenvironment: A Complex However, Targetable Ecosystem. Cells, 9.","DOI":"10.3390\/cells9040976"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Lamora, A., Talbot, J., Mullard, M., Royer, B.L., Redini, F., and Verrecchia, F. (2016). TGF-\u03b2 Signaling in Bone Remodeling and Osteosarcoma Progression. J. Clin. Med., 5.","DOI":"10.3390\/jcm5110096"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.4049\/jimmunol.1301843","article-title":"TGF-\u03b2: Guardian of T cell function","volume":"191","author":"Oh","year":"2013","journal-title":"J. Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"5771","DOI":"10.4049\/jimmunol.180.9.5771","article-title":"IL-10: The master regulator of immunity to infection","volume":"180","author":"Couper","year":"2008","journal-title":"J. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.smim.2014.01.008","article-title":"The two faces of IL-6 in the tumor microenvironment","volume":"26","author":"Fisher","year":"2014","journal-title":"Semin. Immunol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13287-018-0780-x","article-title":"Mesenchymal stem cells in the osteosarcoma microenvironment: Their biological properties, influence on tumor growth, and therapeutic implications","volume":"9","author":"Zheng","year":"2018","journal-title":"Stem Cell Res. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13045-019-0756-z","article-title":"Emerging trends in immunotherapy for pediatric sarcomas","volume":"12","author":"Dyson","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/sj.embor.7400205","article-title":"HMGB1 is an endogenous immune adjuvant released by necrotic cells","volume":"5","author":"Capobianco","year":"2004","journal-title":"EMBO Rep."},{"key":"ref_76","first-page":"461","article-title":"Necrosis of osteosarcoma cells induces the production and release of high-mobility group box 1 protein","volume":"15","author":"Yang","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1158\/1078-0432.CCR-13-0495","article-title":"HMGB1 in cancer: Good, bad, or both?","volume":"19","author":"Kang","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"36","DOI":"10.7150\/jca.5046","article-title":"Dendritic cells in the cancer microenvironment","volume":"4","author":"Ma","year":"2013","journal-title":"J. Cancer"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1365-3083.2009.02308.x","article-title":"How do regulatory t cells work?","volume":"70","author":"Corthay","year":"2009","journal-title":"Scand. J. Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3389\/fimmu.2016.00353","article-title":"T-cell-based immunotherapy for osteosarcoma: Challenges and opportunities","volume":"7","author":"Wang","year":"2016","journal-title":"Front. Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1084\/jem.181.5.1755","article-title":"Interleukin 12 signaling in T helper type 1 (Th1) cells involves tyrosine phosphorylation of signal transducer and activator of transcription (Stat) 3 and Stat4","volume":"181","author":"Jacobson","year":"1995","journal-title":"J. Exp. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"8576","DOI":"10.4049\/jimmunol.181.12.8576","article-title":"IL-12 produced by dendritic cells augments CD8+ T cell activation through the production of the chemokines CCL1 and CCL17","volume":"181","author":"Henry","year":"2008","journal-title":"J. Immunol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"13365","DOI":"10.1038\/s41598-017-14000-z","article-title":"IL-12 stimulates CTLs to secrete exosomes capable of activating bystander CD8+ T cells","volume":"7","author":"Li","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_84","first-page":"1417","article-title":"A mechanistic, predictive model of dose-response curves for cell cycle phase-specific and -nonspecific drugs","volume":"60","author":"Gardner","year":"2000","journal-title":"Cancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"116935","DOI":"10.1016\/j.jns.2020.116935","article-title":"Part II. High-dose methotrexate with leucovorin rescue for severe COVID-19: An immune stabilization strategy for SARS-CoV-2 induced \u2018PANIC\u2019attack","volume":"415","author":"Frohman","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.2042-7158.2012.01567.x","article-title":"Doxorubicin: An update on anticancer molecular action, toxicity and novel drug delivery systems","volume":"65","author":"Tacar","year":"2013","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1039\/c9mt00049f","article-title":"Unexpected therapeutic effects of cisplatin","volume":"11","author":"Raudenska","year":"2019","journal-title":"Metallomics"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1001\/archoto.2009.159","article-title":"Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer","volume":"135","author":"Spanos","year":"2009","journal-title":"Arch. Otolaryngol. Head Neck Surg."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/17486700802216301","article-title":"Mathematical model creation for cancer chemo-immunotherapy","volume":"10","author":"Fister","year":"2009","journal-title":"Comput. Math. Methods Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1158\/1078-0432.CCR-08-0037","article-title":"Pretreatment with cisplatin enhances E7-specific CD8+ T-cell\u2013mediated antitumor immunity induced by DNA vaccination","volume":"14","author":"Tseng","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1038\/s41388-018-0581-9","article-title":"Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles","volume":"38","author":"Grabosch","year":"2019","journal-title":"Oncogene"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"bbaa219","DOI":"10.1093\/bib\/bbaa219","article-title":"A review of digital cytometry methods: Estimating the relative abundance of cell types in a bulk of cells","volume":"22","author":"Le","year":"2020","journal-title":"Brief. Bioinf."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1080\/0284186X.2017.1398411","article-title":"Primary tumor volume measurements in Ewing sarcoma: MRI inter-and intraobserver variability and comparison with FDG-PET","volume":"57","author":"Kasalak","year":"2018","journal-title":"Acta Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1308\/003588406X130651","article-title":"Size matters for sarcomas!","volume":"88","author":"Grimer","year":"2006","journal-title":"Ann. R. Coll. Surg. Engl."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Qiu, Z.Y., Cui, Y., and Wang, X.M. (2019). Natural bone tissue and its biomimetic. Mineralized Collagen Bone Graft Substitutes, Elsevier.","DOI":"10.1016\/B978-0-08-102717-2.00001-1"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1243\/09544119JEIM821","article-title":"Osteoblasts in bone tissue engineering","volume":"224","author":"Jayakumar","year":"2010","journal-title":"Proc. Inst. Mech. Eng. Part H J. Eng. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJM198710223171717","article-title":"Simplified calculation of body-surface area","volume":"317","author":"Mosteller","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1152\/jappl.1966.21.1.167","article-title":"Determination of human body volume from height and weight","volume":"21","author":"Sendroy","year":"1966","journal-title":"J. Appl. Physiol."},{"key":"ref_99","unstructured":"National Center for Biotechnology Information (2021, June 25). PubChem Compound Summary for CID 126941, Methotrexate, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Methotrexate."},{"key":"ref_100","unstructured":"National Center for Biotechnology Information (2021, June 25). PubChem Compound Summary for CID 443939, Doxorubicin Hydrochloride, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Doxorubicin-Hydrochloride."},{"key":"ref_101","unstructured":"National Center for Biotechnology Information (2021, June 25). PubChem Compound Summary for CID 5702198, Cisplatin, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/trans-Dichlorodiamineplatinum_II."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jtbi.2005.06.037","article-title":"Mixed immunotherapy and chemotherapy of tumors: Modeling, applications and biological interpretations","volume":"238","author":"Gu","year":"2006","journal-title":"J. Theor. Biol."},{"key":"ref_103","unstructured":"Perry, M.C. (2008). The Chemotherapy Source Book, Lippincott Williams & Wilkins."},{"key":"ref_104","unstructured":"(2021, June 25). Medscape. Drugs & Diseases, Doxorubicin (Rx). Available online: https:\/\/reference.medscape.com\/drug\/doxorubicin-342120#showall."},{"key":"ref_105","unstructured":"Drugbank Online (2021, June 25). Cisplatin DrugBank Accession Number DB00515. Available online: https:\/\/go.drugbank.com\/drugs\/DB00515."},{"key":"ref_106","unstructured":"Drugbank Online (2021, June 25). Methotrexate DrugBank Accession Number DB00563. Available online: https:\/\/go.drugbank.com\/drugs\/DB00563."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41592-019-0686-2","article-title":"SciPy 1.0: Fundamental algorithms for scientific computing in Python","volume":"17","author":"Virtanen","year":"2020","journal-title":"Nat. Methods"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1049\/iet-syb.2011.0015","article-title":"Sensitivity analysis approaches applied to systems biology models","volume":"5","author":"Zi","year":"2011","journal-title":"IET Syst. Biol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jeconom.2007.12.004","article-title":"Likelihood approximation by numerical integration on sparse grids","volume":"144","author":"Heiss","year":"2008","journal-title":"J. Econ."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1023\/A:1019129717644","article-title":"Numerical integration using sparse grids","volume":"18","author":"Gerstner","year":"1998","journal-title":"Numer. Algorithms"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/S1470-2045(16)30214-5","article-title":"Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): An open-label, international, randomised controlled trial","volume":"17","author":"Marina","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_112","unstructured":"NSW Government (2021, June 25). Osteosarcoma MAP (Methotrexate, DOXOrubicin, cISplatin). Available online: https:\/\/www.eviq.org.au\/medical-oncology\/sarcoma\/bone-sarcoma\/1901-osteosarcoma-map-methotrexate-doxorubicin."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.2147\/OTT.S136621","article-title":"Neoadjuvant chemotherapy combined with limb salvage surgery in patients with limb osteosarcoma of Enneking stage II: A retrospective study","volume":"10","author":"Yuan","year":"2017","journal-title":"OncoTargets Ther."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1021\/acs.molpharmaceut.8b00564","article-title":"Co-delivery of doxorubicin and interferon-\u03b3 by thermosensitive nanoparticles for cancer immunochemotherapy","volume":"15","author":"Yin","year":"2018","journal-title":"Mol. Pharm."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nri2216","article-title":"Immunological aspects of cancer chemotherapy","volume":"8","author":"Zitvogel","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s00262-009-0797-1","article-title":"Immunogenic chemotherapy with cyclophosphamide and doxorubicin against established murine carcinoma","volume":"59","author":"Tongu","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.3892\/ol.2016.4175","article-title":"Dendritic cells combined with doxorubicin induces immunogenic cell death and exhibits antitumor effects for osteosarcoma","volume":"11","author":"Kawano","year":"2016","journal-title":"Oncol. Lett."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.molmed.2008.02.002","article-title":"Immunogenicity of anthracyclines: Moving towards more personalized medicine","volume":"14","author":"Apetoh","year":"2008","journal-title":"Trends Mol. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1158\/1078-0432.CCR-06-2894","article-title":"Doxorubicin Directs the Accumulation of Interleukin-12\u2013Induced IFN\u03b3 into Tumors for Enhancing STAT1\u2013Dependent Antitumor Effect","volume":"13","author":"Zhu","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s00059-011-3470-3","article-title":"Mechanisms and management of doxorubicin cardiotoxicity","volume":"36","author":"Shi","year":"2011","journal-title":"Herz"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/jnci\/djy131","article-title":"Combining tumor microenvironment modulating nanoparticles with doxorubicin to enhance chemotherapeutic efficacy and boost antitumor immunity","volume":"111","author":"Amini","year":"2019","journal-title":"JNCI"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1002\/eji.201242505","article-title":"Lapatinib and doxorubicin enhance the S tat1-dependent antitumor immune response","volume":"43","author":"Tymoszuk","year":"2013","journal-title":"Eur. J. Immunol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.21873\/anticanres.13281","article-title":"Cisplatin augments antitumor T-cell responses leading to a potent therapeutic effect in combination with PD-L1 blockade","volume":"39","author":"Wakita","year":"2019","journal-title":"Anticancer Res."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0889-857X(05)70358-6","article-title":"The mechanism of action of methotrexate","volume":"23","author":"Cronstein","year":"1997","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1084\/jem.20050915","article-title":"Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death","volume":"202","author":"Casares","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00262-003-0391-x","article-title":"Doxorubicin induces specific immune functions and cytokine expression in peritoneal cells","volume":"52","author":"Ujhazy","year":"2003","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"679636fe6caa3db8","DOI":"10.1016\/j.jns.2020.116942","article-title":"Silencing of immune activation with methotrexate in patients with COVID-19","volume":"415","author":"Safavi","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/ard.60.8.729","article-title":"Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis","volume":"60","author":"Cutolo","year":"2001","journal-title":"Ann. Rheum. Dis."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0140-6736(97)02307-6","article-title":"Randomised trial of two regimens of chemotherapy in operable osteosarcoma: A study of the European Osteosarcoma Intergroup","volume":"350","author":"Souhami","year":"1997","journal-title":"Lancet"},{"key":"ref_130","unstructured":"Cancer Therapy Advisor (2021, June 29). Bone Cancer Treatment Regimens. Available online: https:\/\/www.cancertherapyadvisor.com\/home\/cancer-topics\/bone-cancer\/bone-cancer-treatment-regimens\/bone-cancer-treatment-regimens\/."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.1991.9.10.1766","article-title":"Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: A Scandinavian Sarcoma Group study","volume":"9","author":"Saeter","year":"1991","journal-title":"J. Clin. Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13018-020-1576-0","article-title":"The efficacy and safety comparison of first-line chemotherapeutic agents (high-dose methotrexate, doxorubicin, cisplatin, and ifosfamide) for osteosarcoma: A network meta-analysis","volume":"15","author":"Zhang","year":"2020","journal-title":"J. Orthop. Surg. Res."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"e15582","DOI":"10.1097\/MD.0000000000015582","article-title":"Methotrexate, doxorubicin, and cisplatinum regimen is still the preferred option for osteosarcoma chemotherapy: A meta-analysis and clinical observation","volume":"98","author":"Yu","year":"2019","journal-title":"Medicine"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Shaw","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrclinonc.2014.6","article-title":"Cancer Systems Biology: A peek into the future of patient care?","volume":"11","author":"Werner","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtbi.2017.09.031","article-title":"A mathematical model of antibody-dependent cellular cytotoxicity (ADCC)","volume":"436","author":"Hoffman","year":"2018","journal-title":"J. Theor. Biol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jtbi.2016.06.012","article-title":"Mathematical model of tumor\u2013immune surveillance","volume":"404","author":"Mahasa","year":"2016","journal-title":"J. Theor. Biol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jtbi.2015.10.034","article-title":"The re-polarisation of M2 and M1 macrophages and its role on cancer outcomes","volume":"390","author":"Eftimie","year":"2016","journal-title":"J. Theor. Biol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.mbs.2014.04.003","article-title":"A dynamical model of tumour immunotherapy","volume":"253","author":"Frascoli","year":"2014","journal-title":"Math. Biosci."},{"key":"ref_140","unstructured":"Chappell, M., Chelliah, V., Cherkaoui, M., Derks, G., Dumortier, T., Evans, N., Ferrarini, M., Fornari, C., Ghazal, P., and Guerriero, M. (2015, January 14\u201317). Mathematical modelling for combinations of immuno-oncology and anti-cancer therapies. Proceedings of the Report QSP UK Meet, Macclesfield, UK."},{"key":"ref_141","first-page":"346597","article-title":"On study of immune response to tumor cells in prey-predator system","volume":"2014","author":"Kaur","year":"2014","journal-title":"Int. Sch. Res. Not."},{"key":"ref_142","first-page":"56","article-title":"A model of dendritic cell therapy for melanoma","volume":"3","author":"Gallegos","year":"2013","journal-title":"Front. Oncol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1007\/s11538-014-0037-5","article-title":"A validated mathematical model of tumor growth including tumor\u2013host interaction, cell-mediated immune response and chemotherapy","volume":"76","author":"Seoane","year":"2014","journal-title":"Bull. Math. Biol."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Budithi, A., Su, S., Kirshtein, A., and Shahriyari, L. (2021). Data Driven Mathematical Model of FOLFIRI Treatment for Colon Cancer. Cancers, 13.","DOI":"10.3390\/cancers13112632"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"4338","DOI":"10.1038\/s41598-021-83767-z","article-title":"Immune classification of clear cell renal cell carcinoma","volume":"11","author":"Su","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Kirshtein, A., Akbarinejad, S., Hao, W., Le, T., Su, S., Aronow, R.A., and Shahriyari, L. (2020). Data driven mathematical model of colon cancer progression. J. Clin. Med., 9.","DOI":"10.1101\/2020.11.02.365668"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","article-title":"Prevention of High-Dose Chemotherapy\u2013Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition","volume":"114","author":"Cardinale","year":"2006","journal-title":"Circulation"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/00001813-199310000-00001","article-title":"Prevention and treatment of organ toxicity during high-dose chemotherapy: An overview","volume":"4","author":"Blijham","year":"1993","journal-title":"Anti-Cancer Drugs"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/8\/2009\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:41:46Z","timestamp":1760164906000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/8\/2009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,6]]},"references-count":148,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["cells10082009"],"URL":"https:\/\/doi.org\/10.3390\/cells10082009","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,6]]}}}